Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders.
“Annual Meeting”) of Bellerophon Therapeutics, Inc. (the
“Company”), the stockholders approved the three proposals
listed below. Of the 32,988,683 shares of common stock issued,
outstanding and eligible to vote as of the record date of March
16, 2017, a quorum of 24,754,516 shares, or approximately 75% of
the eligible shares, was present in person or represented by
proxy. The final results for the votes regarding each proposal
are set forth in the following tables.
the following nominees to serve on the Company’s board of
directors for a three-year term until the Company’s 2020 annual
meeting of stockholders and until his or her successor is duly
elected and qualified, based on the following votes:
|
|
|
|
|
|||
|
Name
|
Votes For
|
Votes Withheld
|
Broker Non-Votes
|
|||
|
Adam Weinstein
|
14,624,826
|
|
104,686
|
|
10,025,004
|
|
|
Scott Bruder
|
14,612,617
|
116,895
|
10,025,004
|
|||
|
Naseem Amin
|
14,624,726
|
|
104,786
|
|
10,025,004
|
|
Independent Registered Public Accountants of the Company for the
Fiscal Year Ending December 31, 2017: The Company’s stockholders
approved the proposal based on the following votes:
|
|
|
|
|
||||
|
Votes For
|
Votes Against
|
Abstentions
|
Broker Non-Votes
|
||||
|
24,635,076
|
|
72,575
|
|
46,865
|
|
|
Plan to increase the aggregate number of shares available for the
grant of awards to 5,000,000 and to increase the maximum number
of shares available under the annual increase to 3,000,000
shares: The Company’s stockholders approved the proposal based
on the following votes:
|
|
|
|
|
||||
|
Votes For
|
Votes Against
|
Abstentions
|
Broker Non-Votes
|
||||
|
14,303,437
|
|
391,253
|
|
34,822
|
|
10,025,004
|
|
About Bellerophon Therapeutics, Inc. (NASDAQ:BLPH)
Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication. Its INOpulse device has a mechanism that delivers brief, targeted pulses of nitric oxide timed to occur at the beginning of a breath for delivery to the alveoli of the lungs, which minimizes the amount of drug required for treatment. The Company’s second program, BCM, is a medical device focused to prevent congestive heart failure following a ST Segment Elevation Myocardial Infarction (STEMI), which is a type of severe heart attack. The Company’s BCM is in PRESERVATION I clinical trial. Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) Recent Trading Information
Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) closed its last trading session down -0.03 at 1.37 with 251,811 shares trading hands.
